- Home
- FOF vs CLLS Comparison
FOF vs CLLS Comparison
Compare FOF & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
N/A
Current Price
$3.41
Company Overview
Basic Information| Metric | FOF | CLLS |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.4M | 384.3M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | FOF | CLLS |
|---|---|---|
| Price | $12.96 | $3.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 78.9K | 46.6K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 9.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.97 | $1.10 |
| 52 Week High | $15.04 | $5.48 |
Technical Indicators
Market Signals| Indicator | FOF | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 49.07 |
| Support Level | $12.78 | $3.32 |
| Resistance Level | $13.18 | $3.83 |
| Average True Range (ATR) | 0.30 | 0.19 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 32.52 | 62.59 |
Price Performance
Historical Comparison FOF
CLLS
About FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. The Fund's investment objective is to achieve total return, consisting of high current income and potential capital appreciation.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.